ResearcherShaanxi Provincial People's HospitalNo recent work listed

Xi Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9478-0199; OpenAlex author ID A5100442233. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper

Papers 1

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. Co-author DOI 10.4251/wjgo.v14.i7.1252 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Baojun Duan · 1 shared paper, 2022 · strength 0.12
- Paper Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. DOI 10.4251/wjgo.v14.i7.1252 ↗
Yuan Hu · 1 shared paper, 2022 · strength 0.12
- Paper Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. DOI 10.4251/wjgo.v14.i7.1252 ↗
Enxiao Li · 1 shared paper, 2022 · strength 0.12
- Paper Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. DOI 10.4251/wjgo.v14.i7.1252 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.